Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05199090 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT05199090 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 126 participants.
The verdict
NCT05199090, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
This was a multi-center, randomized, placebo-controlled, participant-and-investigator-blinded, sponsor open-label study in obese participants with or without Type 2 Diabetes Mellitus.
Interventions
- DRUG Placebo
- DRUG MBL949
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05199090
The ClinicalTrials.gov registry entry for NCT05199090 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05199090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05199090 about?
NCT05199090 is a clinical study titled "Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM". This was a multi-center, randomized, placebo-controlled, participant-and-investigator-blinded, sponsor open-label study in obese participants with or without Type 2 Diabetes Mellitus.
What is the current status of trial NCT05199090?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2022-02-10. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT05199090?
The interventions under investigation include: Placebo (DRUG), MBL949 (DRUG).
Who is sponsoring clinical trial NCT05199090?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.